

BIBLIOGRAFÍA

1. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. *Hepatology* 1998; 27:1670-1677.
2. Alter MJ. Prevention of spread of hepatitis C. *Hepatology* 2002; 36: S93-S99.
3. Arguedas MR, Johnson A, Eloubeidi MA. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. *Hepatology* 2001; 34: 28-31.
4. Bacon BR. Available options for treatment of interferon nonresponders. *Am J Med* 1999; 107: 67S-70S.
5. Bayas JM, Vilella A. Hepatitis víricas. *Atención Primaria* 2002. Barcelona. 30(8): 514-520.
6. Bekkering FC, Brouwer JT, Leroux-Roels G, et al. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. *J Hepatol* 1998; 28: 960-964.
7. Bruguera M, Bayas JM, Vilella A, et al. Immunogenicity of a combined hepatitis A and hepatitis B vaccine in young adults. *Vaccine* 1996; 14: 1407-1411.
8. Carreno V, Marcellin P, Hadziyannis S, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1999; 30:277-282.
9. Chander C, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: A systematic review. *Hepatology* 2002;36: S135-S144.
10. Cheng SJ, Bonis PAL, Lau J, et al. Interferon and ribavirin for patients who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. *Hepatology* 2001; 33: 231-240.
11. Chousterman M, Auray-Cartier V, Hagege H, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or standard combination therapy. *Hepatology* 2002; 36: 362A.
12. Craxi A, Lo Iacono O. Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck? *J Hepatol* 2001; 35: 527-530.
13. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. *Hepatology* 2002; 36: S121-S128. Dienstag J, Perrillo R, Schiff E, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. *N Engl J Med* 1995; 333:1657-1661.
14. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. *N Engl J Med* 1999; 341:1256-1263.
15. Everson GT. Maintenance interferon for chronic hepatitis C: more issues than answers? *Hepatology* 2000; 32: 436-437.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*. 2002; 347: 975-982.

17. Hadziyannis S, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. *J Hepatol* 1990; 11(Suppl 1):S133-S136.
18. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. *Hepatology* 2000; 32:847-851.
19. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40 kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind multicentre study examining effect of duration of treatment and RBV dose. *J Hepatol* 2002; 36: 3.
20. Honkoop P, de Man RA, Niesters HG, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. *Hepatology* 2000; 32:635-639.
21. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. *Gastroenterology* 1993; 104:1116-1121.
22. Hoofnagle JH. Course and outcome of hepatitis C. *Hepatology* 2002; 36: S21- S30.
23. Iruela López A. Atención al enfermo con hepatitis viral. Guía de actuación en Atención Primaria. Barcelona 2002: 1188-1191.
24. Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1999; 30:238-243.
25. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. *Cochrane Database Syst Rev.* 2002;(2):CD002234. Review.
26. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. *BMJ.* 2001; 323:1151-1155.
27. Knodell RG. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981; 1: 431-435.
28. Krawitt EL, Lidofsky SD, Ferrentino N, et al. Efficacy of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C previously unresponsive to interferon based therapy. *Hepatology* 2002; 36: 295A.
29. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. *Hepatology* 2001; 33:1527-1532.
30. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. *Hepatology* 1997; 26:1621-1625.
31. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. *Hepatology* 1999; 30:567-572.

32. Lindsay K L. Introduction to therapy of hepatitis C. *Hepatology* 2002; 36: S114-S120.
33. Liu JP, Manheimer E, Tsutani K, et al. Medicinal herbs for hepatitis C virus infection. *Cochrane Database Syst Rev.* 2001;(4):CD003183. Review.
34. Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology.* 2001; 34: 1225-1241
35. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-Summary of a workshop. *Gastroenterology* 2001; 120:1828-1853.
36. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet.* 2001; 358: 958-965.
37. McHutchinson JG, Patel K. Future therapy of hepatitis C. *Hepatology* 2002; 36: S245-S252.
38. Myers RP. Interferon for interferon naive patients with chronic hepatitis C. *Cochrane Database Syst Rev.* 2002;(2):CD000370.
39. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002. *Hepatology* 2002; 36: S3-S21.
40. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med* 1996; 334:1422-1427.
41. Oliveri F, Santantonio T, Bellati G, et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. *Am J Gastroenterol* 1999; 94:1366-1372.
42. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B. *J Hepatol* 2001; 34:306-313.
43. Pareja A. Prevención de las enfermedades transmisibles. Actualización PAPPs. *Atención Primaria* 1999; 24: 104-105.
44. Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. *J Hepatol* 1992; 14:221-225.
45. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. *Hepatology* 2002; 36: S65-S74.
46. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. *Gastroenterology* 1995; 109:908-916.
47. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. *Hepatology* 2000; 32:129-134.
48. Peters MG, Terrault NA. Alcohol use and hepatitis C. *Hepatology* 2002; 36: S220-S225.
49. Poynard T, Regimbeau C, Myers RP, et al. Interferon for acute hepatitis C. *Cochrane Database Syst Rev.* 2002;(1):CD000369. Review.

50. Recommendations from the National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. *Hepatology*. 2002; 36: 1039.
51. Saldanha J. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. *J Clin Virol*. 2001; 20: 7-13.
52. San Miguel R, Guillén F, Cabasés JM, et al. Meta-analysis: combination therapy with interferon- α 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. *Aliment Pharmacol Ther* 2002; 16: 1611-1621.
53. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. *J Hepatol* 2000; 32:300-306.
54. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. *Gut* 2000; 46:562-568.
55. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol* 1991; 13: 372-373.
56. Seeff LB. Natural history of chronic hepatitis C. *Hepatology* 2002; 36: S35-S47.
57. Shiffman M. Retreatment of patients with chronic hepatitis C. *Hepatology* 2002; 36: S128-S134.
58. Shiffman M, HALT-C Trial Investigators. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial. *Hepatology* 2002; 36: 295A.
59. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. *Gastroenterology* 1999; 117: 1164-1172.
60. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. *Gastroenterology* 1999; 117: 1164-1172.
61. Shouval D. Is universal vaccination against hepatitis B sufficient for control of HBV infection? Lessons from the immunization campaign in Italy
62. Suarez García E, Romero Gómez M, Grande Santamaría L. Tratamiento actual de la hepatitis B. *Gastroenterol Hepatol* 2001; 24: 35-50.
63. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. *Hepatology* 2001; 33:751-757.
64. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. *Hepatology* 2000; 31:207-210.
65. Wong DK, Cheung AM, O'Rourke MBA. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. *Ann Intern Med* 1993; 119: 312-323.
66. Wright TL. Treatment of patients with hepatitis C and cirrhosis. *Hepatology* 2002; 36: S185-S195.

67. Yagura M, Harada H. Efficacy of amantadine hydrochloride in patients with chronic hepatitis C. *J Gastroenterol* 2001; 36: 792-793.
68. Yang H, Westland CE, Delaney IV WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. *Hepatology* 2002; 36:464-473.
69. Zamir C, Risphon S, Zamir D et al. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. *Eur J Clin Microbiol* 2001;20:185-187.

Bibliografía específica del Anexo 3

- 1 Ramesh V , Saraswat S, Choudhury N, Gupta RK. Relationship of serum alanine aminotransferase (ALT) to body mass index (BMI) in blood donors: the need to correct ALT for BMI in blood donor screening. *Transfus Med* 1995;5:273-4.
- 2 Lozano M, Cid J, Bedini JL, Mazzara R, Giménez N, Mas E, Ballesta A, Ordinas A. Study of serum alanine aminotransferase levels in blood donors in Spain. *Haematologica* 1998;83:237-9.
- 3 Leclercq I, Horsmans Y, De Bruyere M, Geubel AP. Influence of body mass index, sex and age on serum alanine aminotransferase (ALT) level in healthy blood donors. *Acta Gastroenterol Belg* 1999;62:16-20.
- 4 Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Samsonetti N, Opolon P. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. *Hepatology* 1998;27:1213-9.
- 5 Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. *Dig Dis Sci* 1993;38:2145-50.
- 6 Gurlek A, Cubankara V, Bayraktan M. Liver tests in hiperthyroidism effect of antithyroid therapy. *J Clin Gastroenterol* 1997;24:180-3.
- 7 Tajiri J, Shimada T, Naomi S, Umeda T, Sato T. Hepatic dysfunction in primary hypothyroidism. *Endocrinolog Jpn* 1984;31:83-91.
- 8 Bayraktar M, Van Thiel DH. Abnormalities in measures of liver function and injury in thyroid disorders. *Hepatogastroenterology* 1997;44:1614-8.
- 9 Novacek G, Miehsler W, Wrba F, Ferenci P, Penrer E, Vogelsang H. Prevalence and clinical importance of hipertransaminasaemia in coeliac disease. *Eur J Gastroenterol Hepatol* 1999;11:283-8.
- 10 Dickey W, McMillan SA, Collins JS, Watson RG, McLoughlin JC, Love AH. Liver abnormalities associated with celiac sprue. How common are they, what is their significance, and what do we do about them?. *J Clin Gastroenterol* 1995;20:290-2.
- 11 Jacobsen MB, Fausa O, Elgio K, Schrupf E. Hepatic lesions in adult coeliac disease. *Scand J Gastroenterol* 1990;25:656-62.
- 12 Volta U, De Franceschi L, Lani F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. *Lancet* 1998;352:26-9.
- 13 Bardella MT, Vecchi M, Conte D, Del Ninno E, Fraquelli M, Pacchetti S, Minola E, Landoni M, Cesana BM, De Franchis R. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. *Hepatology* 1999;29:654-7.
- 14 Achiron A, Barak Y, Magal N, Shohat M, Cohen M, Bavar R, Gadoth N. Abnormal liver test result in myotonic dystrophy. *J Clin Gastroenterol* 1998;26:292-5.

- 15 Prella A, Rigoletto C, Moggio M, Sciacco M, Comi GP, Ciscato P, Fagiolani G, Rapuzzi S, Bignotti V, Scarlato G. Asymptomatic familial hyperCPKemia associated with desmin accumulation in skeletal muscle. *J Neurol Sci* 1996;140:132-136
- 16 Morrone A, Zammarchi E, Scacheri PC, Donati MA, Hoop RC, Servidei S, Galluzzi G, Hoffman EP. Asymptomatic dystrophinopathy. *Am J Med Genet* 1997;69:261-267.
- 17 Litin SC, O'Brien JF, Pruett S, Forsman RW, Burnit MF, Bartholomew LG, Baldus WP. Macroenzymeas a cause of unexplained elevation of aspartate aminotransferase. *Mayo Clin Proc* 1987;62:681-87.
- 18 Foust RT, O'Brien JF, Schiff ER. Isolated aspartate aminotransferase elevation due to macroenzyme formation with liver biopsy correlation. *Am J Gastroenterol* 1990;85:88-90.
- 19 Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology* 1995;22:1714-1719.
- 20 Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. *Hum Pathol* 1989;20:594-598.
- 21 Bacon BR, Farshvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* 1994;107:1103-1109.
- 22 Scheuer PJ. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. *Mayo Clin Proc* 1998;73:179-183.
- 23 Ludwig J, Weisner RH, LaRusso NF. Idiopathic adulthood ductopenia: A cause of chronic cholestatic liver disease and biliary cirrhosis. *J Hepatol* 1988;7:193-199.
- 24 Moreno A, Carreño V, Cano A, Gonzalez C. Idiopathic biliary ductopenia in adults without symptoms of liver disease. *N Engl J Med* 1997;336:835-838.
- 25 Ishak KG. Sarcoidosis of the liver and bile ducts. *Mayo Clin Proc* 1998;73:467-472.
- 26 Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. *Hepatology* 1993;17:70-77.